DUBLIN–(BUSINESS WIRE)–The “Musculoskeletal Pain – Epidemiology Forecast to 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This ‘Musculoskeletal Pain – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Musculoskeletal Pain in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Musculoskeletal Pain: Epidemiology
The Musculoskeletal Pain epidemiology division provides insights into the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.
Companies such as Mesoblast, Mitsubishi Tanabe Pharma, Regeneron Pharmaceuticals, Ampio Pharmaceuticals, Charleston Laboratories, Sorrento Therapeutics, Centrexion Therapeutics, MDM S.p.A., Braeburn Pharmaceuticals, and Taiwan Liposome Company are actively involved in developing therapies for the treatment of MSP.
It is anticipated that with the launch of key assets like Ampion (Ampio Pharmaceuticals), CAM2038 (Braeburn Pharmaceuticals), CNTX-4975 (Centrexion Therapeutics), and fasinumab, the market size would witness expedited growth during the forecasted period.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted Musculoskeletal Pain epidemiology segmented as the Diagnosed Prevalent cases of Musculoskeletal Pain, Age-specific cases of Musculoskeletal Pain, and Gender-specific cases of Musculoskeletal Pain. The report includes the prevalent scenario of Musculoskeletal Pain in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country-wise Musculoskeletal Pain Epidemiology
The epidemiology segment also provides the Musculoskeletal Pain epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total diagnosed prevalent population of Musculoskeletal Pain in the 7MM countries was estimated to be 145,426,730 cases in 2020.
As per the estimates, the United States had the largest diagnosed prevalence of Musculoskeletal Pain in 2020. Among the EU5 countries, France had the largest diagnosed prevalent population of Musculoskeletal Pain with 12,649,387 cases, followed by Italy in 2020. On the other hand, Germany had the lowest diagnosed prevalent population with 8,642,397 cases in 2020.
Scope of the Report
- Musculoskeletal Pain report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
- Musculoskeletal Pain Epidemiology Report and Model provide an overview of the risk factors and global Musculoskeletal Pain trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report provides insight into the historical and forecasted patient pool of Musculoskeletal Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
- The report helps recognize the growth opportunities in the 7MM concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of Musculoskeletal Pain.
- The report provides the segmentation of the Musculoskeletal Pain epidemiology by diagnosed prevalent cases of Musculoskeletal Pain in the 7MM.
- The report provides the segmentation of the Musculoskeletal Pain epidemiology by the age-specific cases of Musculoskeletal Pain in the 7MM
- The report provides the segmentation of the Musculoskeletal Pain epidemiology by the gender-specific cases of Musculoskeletal Pain in the 7MM.
Key Topics Covered:
1. Report Introduction
2. Executive Summary of Musculoskeletal Pain
3. Disease Background and Overview
3.1. Introduction
3.2. Types of Musculoskeletal Pain
3.3. Signs and Symptoms of Musculoskeletal Pain
3.4. Causes of Musculoskeletal Pain
3.5. Pathophysiology of Musculoskeletal Pain
3.6. Diagnosis of Musculoskeletal Pain
3.7. Biomarkers for Musculoskeletal Pain
3.8. Treatment of Musculoskeletal Pain
3.9. Guidelines for Management for Musculoskeletal pain
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Diagnosed Prevalent cases of Musculoskeletal Pain
4.3. Epidemiology of Musculoskeletal Pain
4.4. The United States
4.4.1. Diagnosed prevalent cases of Musculoskeletal Pain in the United States
4.4.2. Age-specific Cases of Musculoskeletal Pain in the United States
4.4.3. Gender-specific Prevalence of Musculoskeletal Pain in the United States
4.5. EU5
4.5.1. Germany
4.5.1.1. Diagnosed Prevalent Cases of Musculoskeletal Pain in Germany
4.5.1.2. Age-specific Cases of Musculoskeletal Pain in Germany
4.5.1.3. Gender-specific cases of Musculoskeletal Pain in Germany
4.5.2. France
4.5.3. Italy
4.5.4. Spain
4.5.5. The United Kingdom
4.6. Japan
5. Organizations contributing towards the fight against Musculoskeletal Pain
6. Case Reports
7. Patient Journey
8. KOL Views
9. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5e3prp
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
This is a syndicated feed and is brought to you in partnership with Business Wire. Global Pharma Times and Trade News Network are not responsible for any claims made in this story.
